|
Name |
Stigmasterol
|
Molecular Formula | C29H48O | |
IUPAC Name* |
(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
|
SMILES |
CC[C@H](/C=C/[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C
|
|
InChI |
InChI=1S/C29H48O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-10,19-21,23-27,30H,7,11-18H2,1-6H3/b9-8+/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1
|
|
InChIKey |
HCXVJBMSMIARIN-PHZDYDNGSA-N
|
|
Synonyms |
STIGMASTEROL; 83-48-7; Stigmasterin; beta-Stigmasterol; Stigmasta-5,22-dien-3-ol, (3b,22E)-; Stigmasta-5,22-dien-3beta-ol; .beta.-Stigmasterol; (24S)-5,22-Stigmastadien-3beta-ol; Stigmasta-5,22-dien-3-beta-ol; Stigmasta-5,22-dien-3-ol, (3beta,22E)-; (3beta,22E)-Stigmasta-5,22-dien-3-ol; 99WUK5D0Y8; CHEBI:28824; Stigmasta-5,22E-dien-3beta-ol; NSC 8095; NSC-8095; .delta.5,22-Stigmastadien-3.beta.-ol; (3.beta.,22E)-Stigmasta-5,22-dien-3-ol; Stigmasta-5,22-dien-3-ol; MFCD00003630; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 3beta-Hydroxy-24-ethyl-5,22-cholestadiene; UNII-99WUK5D0Y8; Serposterol; b-stigmasterol; Stigmasta-5,22-dien-3.beta.-ol; CCRIS 7476; D5-Stigmasterol; HSDB 7683; Delta5-Stigmasterol; EINECS 201-482-7; STIMASTEROL; Stigmasterol, ~95%; Stigmasta-5,22-dien-3-ol, (3beta)-; STIGMASTEROL [MI]; STIGMASTEROL [HSDB]; Wulzen anti-stiffness factor; SCHEMBL23999; .DELTA.5-STIGMASTEROL; STIGMASTEROL [WHO-DD]; stigmasta-5,22t-dien-3b-ol; CHEMBL400247; stigmasta-5,22-dien-3-b-ol; DTXSID801015733; Delta5,22-Stigmastadien-3beta-ol; HY-N0131; ZINC4096712; (24S)-5,22-stigmastadien-3b-ol; BDBM50376364; HB4095; LMST01040123; s2361; STL570256; 24aFH-stigmasta-5,22t-dien-3b-ol; AKOS022168193; CS-7746; (22E)-stigmasta-5,22-dien-3beta-ol; (24S)-Stigmast-5,22-dien-3beta-ol; (24xH)-stigmasta-5,22t-dien-3b-ol; 24-Ethyl-5,22-cholestadien-3beta-ol; 5,22-Cholestadien-24-ethyl-3beta-ol; GUINEA-PIG-ANTI-STIFFNESS FACTOR; (24aFH)-stigmasta-5,22t-dien-3b-ol; (24x)-ethylcholesta-5,22-dien-3b-ol; NCGC00142599-03; (3b,22E)-stigmasta-5,22-dien-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5S,E)-5-ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 14-((2E)(4S,1R)-4-ethyl-1,5-dimethylhex-2-enyl)(1S,5S,10S,11S,2R,14R,15R)-2,15 -dimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-7-en-5-ol; 24x-24-ethylcholest-5,22-dien-3b-ol; AS-15473; 24-Ethyl-5,22-cholestadien-3.beta.-ol; 5,22-Cholestadien-24beta-ethyl-3beta-ol; rac-(24xH)-stigmasta-5,22t-dien-3b-ol; (24S)-24-Ethylcholesta-5,22-dien-3beta-ol; C05442; Q425004; STIGMASTEROL (CONSTITUENT OF PYGEUM) [DSC]; Q-201746; STIGMASTEROL (CONSTITUENT OF SAW PALMETTO) [DSC]; 3.BETA.-HYDROXY-24-ETHYL-.DELTA.(SUP 5,22)-CHOLESTADIENE; Stigmasterol, certified reference material, 10 mg/mL in chloroform; 17-(4-ethyl-1,5-dimethyl-hex-2-enyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol
|
|
CAS | 83-48-7 | |
PubChem CID | 5280794 | |
ChEMBL ID | CHEMBL400247 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 412.7 | ALogp: | 8.6 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 20.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.443 |
Caco-2 Permeability: | -4.576 | MDCK Permeability: | 0.00001440 |
Pgp-inhibitor: | 0.951 | Pgp-substrate: | 0.936 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.992 |
30% Bioavailability (F30%): | 0.552 |
Blood-Brain-Barrier Penetration (BBB): | 0.178 | Plasma Protein Binding (PPB): | 88.12% |
Volume Distribution (VD): | 1.629 | Fu: | 1.09% |
CYP1A2-inhibitor: | 0.093 | CYP1A2-substrate: | 0.651 |
CYP2C19-inhibitor: | 0.17 | CYP2C19-substrate: | 0.924 |
CYP2C9-inhibitor: | 0.346 | CYP2C9-substrate: | 0.083 |
CYP2D6-inhibitor: | 0.295 | CYP2D6-substrate: | 0.59 |
CYP3A4-inhibitor: | 0.832 | CYP3A4-substrate: | 0.815 |
Clearance (CL): | 4.515 | Half-life (T1/2): | 0.036 |
hERG Blockers: | 0.31 | Human Hepatotoxicity (H-HT): | 0.188 |
Drug-inuced Liver Injury (DILI): | 0.237 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.386 | Maximum Recommended Daily Dose: | 0.973 |
Skin Sensitization: | 0.912 | Carcinogencity: | 0.1 |
Eye Corrosion: | 0.023 | Eye Irritation: | 0.08 |
Respiratory Toxicity: | 0.807 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004758 | 0.852 | D0Y7LD | 0.729 | ||||
ENC001558 | 0.852 | D0B4RU | 0.581 | ||||
ENC001846 | 0.794 | D0K0EK | 0.495 | ||||
ENC003369 | 0.794 | D0G8OC | 0.430 | ||||
ENC001008 | 0.729 | D02STN | 0.398 | ||||
ENC001107 | 0.729 | D06JPB | 0.393 | ||||
ENC005068 | 0.717 | D06XMU | 0.392 | ||||
ENC000961 | 0.716 | D0G5CF | 0.364 | ||||
ENC002290 | 0.708 | D07BSQ | 0.361 | ||||
ENC003458 | 0.694 | D0G3SH | 0.356 |